# A Study to Learn About How BAY 3283142 Moves Into, Through, and Out of the Body After a Single Dose in Participants With Reduced Liver Function Compared to Participants With Normal Liver Function

> **NCT06402721** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 24 (actual)

## Conditions studied

- Chronic Kidney Disease
- Hepatic Impairment

## Interventions

- **DRUG:** BAY3283142

## Key facts

- **NCT ID:** NCT06402721
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-05-17
- **Primary completion:** 2025-02-24
- **Final completion:** 2025-02-24
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2025-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06402721

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06402721, "A Study to Learn About How BAY 3283142 Moves Into, Through, and Out of the Body After a Single Dose in Participants With Reduced Liver Function Compared to Participants With Normal Liver Function". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06402721. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*